Log in
2024年中国创新药械出海趋势与策略白皮书-锦天城x海通证券x沙利文
English body is not available for this report yet; showing the Chinese version. View in Chinese
常见问题
- 这份报告主要研究什么？
- 《2024年中国创新药械出海趋势与策略白皮书-锦天城x海通证券x沙利文》主要讨论：中国医疗产品凭借性价⽐和技术优势在国际市场崭露头⻆，政府⽀持和全球化趋势为其出海创造了有利条件。其中，药物出海中License-out占据主导地位，管线BD交易使得中国企业的创新药物加速进⼊国际市场…
- 报告来自哪个机构？何时发布？
- 来源机构：锦天城x海通证券x沙利文。
Copyright notice
This report is aggregated from publicly available internet sources. Copyright belongs to the original authors or rights holders. If you are a rights holder and believe content on this platform infringes your rights, please email copyright@ruishubaogao.com . We will remove the content promptly after verification.